WooGene B&G Co (018620) Fair Value & Analysis
Healthcare · KR · Market cap 17.7B KRW
Fair value as of: Jun 24, 2026
Analysis
WooGene B&G Co (018620) currently trades at 2,245 KRW, while our model-based Fair Value estimate is 1,050 KRW — implying the stock looks roughly 53.2% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is WooGene B&G Co (018620) undervalued?
What is the fair value of 018620?
What is the quality score of 018620?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.